Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma

Published:2020-08-27 Issue:14 Volume:61 Page:3378-3386
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chinen Yoshiaki¹²,Tanba Kazuna¹,Takagi Ryo³,Uchiyama Hitoji⁴,Uoshima Nobuhiko⁵,Shimura Kazuho⁶,Fuchida Shin-ichi⁷,Kiyota Miki⁸,Nakao Mitsushige⁹,Tsukamoto Taku²,Shimura Yuji²,Kobayashi Tsutomu²,Horiike Shigeo²,Wada Katsuya⁸,Shimazaki Chihiro⁷,Kaneko Hiroto⁶,Kobayashi Yutaka⁵,Taniwaki Masafumi⁶,Yokota Isao³,Kuroda Junya²,

Affiliation:

1. Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan

2. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

3. Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

4. Department of Hematology, Japan Red Cross Kyoto Daiichi Hospital, Kyoto, Japan

5. Department of Hematology, Japan Red Cross Kyoto Daini Hospital, Kyoto, Japan

6. Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan

7. Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan

8. Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan

9. Department of Internal Medicine, Otsu Municipal Hospital, Otsu, Japan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1811862

Reference36 articles.

1. Multiple primary tumours: challenges and approaches, a review

2. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment

3. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

4. Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma

5. Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma;ESMO Open;2024-02

2. Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database;BMJ Open;2022-09